Company news

Larimar Therapeutics, Inc. news in 2022

Larimar Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

November 9, 2022

Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601

October 19, 2022

Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

October 18, 2022

Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

September 15, 2022

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

September 13, 2022

Larimar Therapeutics Announces $70 Million Underwritten Offering

September 13, 2022

Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results

August 10, 2022

Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders

July 27, 2022

Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts

June 27, 2022

Larimar Therapeutics Announces Upcoming Scientific Conference Presentations

June 1, 2022

Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress

May 18, 2022

Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results

May 11, 2022

Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results

March 24, 2022

Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

February 13, 2022

Decks in 2022